Drug Profile
Budiodarone - Espero BioPharma
Alternative Names: ATI-2042Latest Information Update: 11 Mar 2024
Price :
$50
*
At a glance
- Originator ARYx Therapeutics
- Developer Espero BioPharma
- Class Benzofurans; Class III antiarrhythmics; Small molecules
- Mechanism of Action Calcium channel antagonists; Potassium channel antagonists; Sodium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Atrial fibrillation
- Discontinued Ventricular tachycardia